Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

European Authority Gives Thumbs Down To PTC Therapeutics' Duchenne Therapy; Analyst Says It Can Overturn The Challenge

Published 15/09/2023, 19:05
© Reuters.  European Authority Gives Thumbs Down To PTC Therapeutics' Duchenne Therapy; Analyst Says It Can Overturn The Challenge
PTCT
-

Benzinga - by Vandana Singh, Benzinga Editor.

Friday morning, the Committee for Medicinal Products for Human Use of the European Medicines Agency gave a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of PTC Therapeutics Inc's (NASDAQ: PTCT) Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy.

The negative opinion also applies to the renewal of the existing conditional authorization.

PTC plans to submit a request for re-examination. Translarna will remain on the market and available until the re-examination process is completed.

Following the re-examination process, the opinion would be expected to occur in January 2024, with the European Commission ratifying the opinion within the following 67 days.

Translarna received conditional marketing authorization in Europe in 2014 based on the results of Study 007, and the conditional authorization was renewed in 2017.

PTC agreed to conduct a third placebo-controlled trial, Study 041, to renew the conditional marketing authorization.

PTC shared the results of Study 041, which included nominally statistically significant results on several key endpoints in the overall enrolled Intent-to-Treat population of 359 boys, even though it did not meet statistical significance in the primary analysis subgroup.

William Blair considers the update to be unexpected and unfortunate; it's essential to note that PTC has previous experience in overturning the CHMP's stance on Translarna.

In 2014, the CHMP initially issued a negative opinion regarding Translarna's conditional marketing authorization, and PTC successfully reversed that decision.

Moreover, in 2017, PTC effectively negotiated the renewal of Translarna's conditional marketing authorization, which included the commitment to conduct a long-term post-authorization trial.

Additionally, the analyst finds the change in rapporteur for the re-examination process and the positive data from all three studies, particularly when analyzing the 300-400m 6MWT baseline population as the primary group, to be supportive of the potential to overturn the CHMP's decision.

Price Action: PTCT shares are down 28.70% at $26.66 on the last check Friday.

Latest Ratings for PTCT

DateFirmActionFromTo
Feb 2022JP MorganMaintainsOverweight
Feb 2022BarclaysMaintainsEqual-Weight
Oct 2021Raymond JamesMaintainsOutperform
View More Analyst Ratings for PTCT

View the Latest Analyst Ratings

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.